VYNE Therapeutics Inc (NASDAQ: VYNE) stock closed at $3.51 on 11/10/23 after a major increase of 15.3%. The stock has performed in line with the market over the last nine months and has risen 15.5% during the last week.
Current PriceTarget Research Rating
VYNE’s future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to continue to be a modest Value Eraser.
VYNE Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. VYNE Therapeutics has a neutral Power Rating of 42 but a very low Appreciation Score of 14, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment